Move at the Speed of Experience™
Christina J. Ansted, MPH, CCMEP
Co-Founder and CEO
Christina is a multifaceted biotech executive with expertise in global commercialization, medical communications and rare disease. Adept at building high-performance teams that drive value across an organization, Christina is deeply inspired to create a legacy of innovation by changing the approach to commercialization, improving rates of success and impacting the lives of patients worldwide.
Michael C. Janes
Co-Founder and CRO
Head, Private Market Practice
Michael has led global teams focused on global business development, private equity, sales operations, training and development, and business process optimization. With a commitment to outcomes and outstanding relationship management, Michael’s vision is to drive value creation for private market clients with biotech centric portfolios.
Daniel P. Silver, Esq.
Chief of Staff
Dan, an attorney by training, brings his legal expertise and experience as a biotech coordinator to support daily operations of the leadership team, executive corporate functions, vendor and partner relations and strategic implementation.
Chief Commercial & Strategy Officer
Greg is an exceptional marketing and commercial strategy executive with extensive experience in large pharma and startup biotechs leading cross-functional teams for pre-launch, launch, re-launch and in-market brands in primary care, oncology, virology, respiratory, gene therapy and rare disease both globally and in the U.S., in addition to divisional/regional sales management expertise.
Edward Dow, MD
Chief Medical Officer
Edward is a highly experienced physician executive and practicing Hematologist-Oncologist with extensive expertise in global medical affairs and clinical development providing data generation and synthesis for medical support of new product commercialization. Ed continues to see patients with cancer and blood diseases on a part-time basis.
Paresh Soni, MD, PhD
SVP, Clinical and Corporate Development
Paresh is a board-certified internist and gastroenterologist with broad medical/scientific and corporate management experience having led global multidisciplinary teams across the development spectrum – from translational medicine to successful approval.
SVP, MedTech Ventures
Barry is a senior level medical device executive with demonstrated leadership in sales and marketing strategy, business and product development, strategic analysis and growth planning and oversees all RCP medical device engagements.
Steve M. Palmisano, ISMPP CMPP
SVP, Medical and Scientific Communications
Steve is a seasoned healthcare communications executive known for innovative and alternative approaches. A strategic thinker, Steve leverages his operational and technology expertise to improve work efficiency and notably was the creator of the pharma industry’s 1st scientific communications platform and now industry standard.
Kevin W. Mayo, PhD, EJD
VP, Global Market Access and Health Economics
Kevin’s extensive expertise in market access, pricing and reimbursement, HEOR, health policy and government affairs, and patient /medical advocacy enables him to maximize global revenue potential and market share growth. He leads patient and market access strategy and implementation.
Jennifer King, MBA
VP, Global Pricing and Payer Insights
Jennifer brings a wealth of commercial and market access experience across oncology and orphan drugs. She is well-versed in global, EMEA and Asia Pacific/Japan markets supporting pricing and market access strategies in both strategic development and implementation with the goal of achieving optimal access for all stakeholders.
SD, Reimbursement and Market Access Strategy
Joseph is a veteran market access, reimbursement and government affairs expert with interests in diagnostic and medical device strategy, HEOR and payer/provider market research. He leads projects focused on coding, coverage, payment, evidence generation, launch plans and value communication strategies.
Tom Lo, MS, MBA
Head, Clinical Science and Diagnostic Strategy
Tom has exceptional experience expanding the treatable patient population for therapeutics. With a focus on building awareness for diagnostic testing to enable optimal patient identification and timely therapy, Tom has led diagnostic strategy for eight rare diseases and provided leadership to develop and implement diagnostic strategy supporting field implementation and training across a myriad of therapeutic areas. He applies his considerable field sales acumen to ensure successful collaboration, integration, and execution of strategic diagnostic initiatives.